Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Makoto Maemondo et al. N Engl J Med. .
Free article

Abstract

Background: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy.

Methods: We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel. The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.

Results: In the planned interim analysis of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the standard-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study. The gefitinib group had a significantly longer median progression-free survival (10.8 months, vs. 5.4 months in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001). The median overall survival was 30.5 months in the gefitinib group and 23.6 months in the chemotherapy group (P=0.31). The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%). One patient receiving gefitinib died from interstitial lung disease.

Conclusions: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy. (UMIN-CTR number, C000000376.)

PubMed Disclaimer

Comment in

  • Interstitial lung disease and gefitinib.
    Murashige N, Tanimoto T, Oshima Y. Murashige N, et al. N Engl J Med. 2010 Oct 14;363(16):1578-9; author reply 1579-80. doi: 10.1056/NEJMc1008506. N Engl J Med. 2010. PMID: 20942679 No abstract available.
  • Interstitial lung disease and gefitinib.
    Lim KH, Chang YH. Lim KH, et al. N Engl J Med. 2010 Oct 14;363(16):1579; author reply 1579-80. doi: 10.1056/NEJMc1008506. N Engl J Med. 2010. PMID: 20949670 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms